Skip to content
Screener

United Therapeutics UTHR Q1 2026 earnings

Reported May 6, 2026 · Before market open

Revenue$781.5MMiss by $15.9M
EPS$5.82Miss by $1.18
Revenue estimate$797.4M
EPS estimate$7.00

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$789.5M
EPS estimate$6.44

Financials

Q1 2026

Income statement

See full
Revenue$781.5M-1.6%
Gross profit$648.1M-7.7%
Operating income$325.8M-14.9%
Net income$274.9M-14.7%
EPS (diluted)$5.82-12.2%

Balance sheet

See full
Cash & equivalents$1.3B-32.6%
Total equity$5.9B-13.3%
Total assets$6.7B-13.3%

Cash flow

See full
Operating cash flow$463.3M+0.5%
CapEx$100.8M+34.6%
Free cash flow$362.5M-6.2%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$25.99B+87.7%
P/E20.2×+8.8×
P/S8.2×+3.6×

Profitability

See full
Gross margin86.6%-2.4pp
Operating margin45.3%-1.6pp
Net margin40.6%+0.2pp
FCF margin32.1%-5.6pp

Returns & leverage

See full
Return on equity20.3%+0.3pp
Current ratio4.8×-0.7×

Segments

By product

See full
Tyvaso DPI$330.3M+9.2%
Orenitram$135.6M+12.3%
Nebulized Tyvaso$127.2M-22.3%
Remodulin$126.6M-8.4%
Unituxin$53.6M-7.9%

FAQ

When did United Therapeutics report Q1 2026 earnings?
United Therapeutics (UTHR) reported Q1 2026 earnings on May 6, 2026 before market open.
What were United Therapeutics's Q1 2026 revenue and EPS?
United Therapeutics reported revenue of $781.5M and eps of $5.82 for Q1 2026.
Did United Therapeutics beat estimates in Q1 2026?
Revenue missed the consensus estimate of $797.4M by $15.9M. EPS missed the consensus estimate of $7.00 by $1.18.
How did United Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 1.6% from $794.4M a year earlier and eps declined 12.2% from $6.63.
Where can I find United Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001082554-26-000021) and the 10-Q periodic report (0001082554-26-000020) directly on SEC EDGAR. The filing index links above go to sec.gov.